A phase i study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 643-651

  Hebb, Jonathan ^a   Assouline, Sarit ^a   Rousseau, Caroline ^a   Desjardins, Pierre ^b   Caplan, Stephen ^a   Egorin, Merrill J ^c   Amrein, Lilian ^a   Aloyz, Raquel ^a   Panasci, Lawrence ^a  

^a MCGILL UNIVERSITY   (Canada)

^b HÔPITAL CHARLES LEMOYNE   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alkylating agent; Chlorambucil; Chronic lymphocytic leukemia; Imatinib; Phase I trial; Tyrosine kinase inhibitor

Indexed keywords

CHLORAMBUCIL; FLUDARABINE; IMATINIB; RITUXIMAB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PATIENT; CHEMOSENSITIZATION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEARTBURN; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEG EDEMA; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TASTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEAKNESS; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RAD51 RECOMBINASE; RECOMBINATION, GENETIC; TREATMENT OUTCOME; VIDARABINE;

EID: 80054694131     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1530-7     Document Type: Article

References (23)

1. Dighiero G (2005) CLL biology and prognosis. Hematology Am Soc Hematol Educ Program 278-284
2. B Eichhorst V Goede M Hallek 2009 Treatment of elderly patients with chronic lymphocytic leukemia Leuk Lymphoma 50 171 178 19197731 10.1080/10428190802688517 1:CAS:528:DC%2BD1MXltVaitbg%3D
3. A Begleiter M Mowat L Israels J Johnston 1996 Chlorambucil in chronic lymphocytic leukemia: mechanism of action Leuk Lymphoma 123 187 201 10.3109/10428199609054821
4. L Panasci J Paiement G Christodoulopoulos A Belenkov A Malapetsa R Aloyz 2001 Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair Clin Cancer Res 7 454 461 11297233 1:CAS:528: DC%2BD3MXjtVOgtb8%3D
5. S Torres-Garcia L Cousineau S Caplan L Panasci 1989 Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links Biochem Pharmacol 38 3122 3123 2783167 10.1016/0006-2952(89)90025-7 1:CAS:528:DyaL1MXls1Kqtro%3D
6. T Takenaka I Yoshino H Kouso T Ohba T Yohena A Osoegawa, et al. 2007 Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer Int J Cancer 121 895 900 17417781 10.1002/ijc.22738 1:CAS:528:DC%2BD2sXotlequ7k%3D
7. G Chen S Yuan W Liu Y Xu K Trujillo B Song, et al. 1999 Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl J Biol Chem 274 12748 12752 10212258 10.1074/jbc.274.18.12748 1:CAS:528: DyaK1MXjtFGns7k%3D
8. S Yuan H Chang E Lee 2003 Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM(-/-) and c-Abl(-/-) cells Mutat Res 525 85 92 12650908 1:CAS:528:DC%2BD3sXitFamtrs%3D
9. H Shimizu M Popova F Fleury M Kobayashi N Hayashi I Sakane, et al. 2009 c-ABL tyrosine kinase stabilizes RAD51 chromatin association Biochem Biophys Res Commun 382 286 291 19285032 10.1016/j.bbrc.2009.03.020 1:CAS:528: DC%2BD1MXkt1Slu78%3D
10. F Drabløs E Feyzi P Aas C Vaagbø B Kavli M Bratlie, et al. 2004 Alkylation damage in DNA and RNA-repair mechanisms and medical significance DNA Repair (Amst) 3 1389 1407 10.1016/j.dnarep.2004.05.004
11. K Miyagawa 2008 Clinical relevance of the homologous recombination machinery in cancer therapy Cancer Sci 99 187 194 17953711 10.1111/j.1349-7006. 2007.00644.x 1:CAS:528:DC%2BD1MXjs1ygt7k%3D
12. J Goldman 2009 Initial treatment for patients with CML Hematology Am Soc Hematol Educ Program 9 453 460
13. X An AK Tiwari Y Sun PR Ding CR Ashby Jr. ZS Chen 2010 BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia. A review Leuk Res 34 10 1255 1268 20537386 10.1016/j.leukres.2010.04.016 1:CAS:528:DC%2BC3cXhtV2itLnO
14. R Aloyz K Grzywacz Z Xu M Loignon M Alaoui-Jamali L Panasci 2004 Imatinib sensitizes CLL lymphocytes to chlorambucil Leukemia 18 409 414 14712290 10.1038/sj.leu.2403247 1:CAS:528:DC%2BD2cXhsV2qsL8%3D
15. J Russell K Brady W Burgan M Cerra K Oswald K Camphausen, et al. 2003 Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity Cancer Res 63 7377 7383 14612536 1:CAS:528:DC%2BD3sXovVGltL0%3D
16. K Rai B Peterson F Appelbaum J Kolitz L Elias L Shepherd, et al. 2000 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 1750 1757 11114313 10.1056/ NEJM200012143432402 1:CAS:528:DC%2BD3cXptVehs7k%3D
17. B Cheson J Bennett M Grever N Kay M Keating S O'Brien, et al. 1996 National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 4990 4997 8652811 1:CAS:528:DyaK28XjsFGisb8%3D
18. R Parise R Ramanathan M Hayes M Egorin 2003 Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma J Chromatogr B Analyt Technol Biomed Life Sci 791 39 44 12798163 10.1016/S1570-0232(03)00206-X 1:CAS:528:DC%2BD3sXkt1Okurw%3D
19. B Peng P Lloyd H Schran 2005 Clinical pharmacokinetics of imatinib Clin Pharmacokinet 44 879 894 16122278 10.2165/00003088-200544090-00001 1:CAS:528:DC%2BD2MXhtFSktbzF
20. J Friedberg J Sharman J Sweetenham P Johnston J Vose A Lacasce, et al. 2010 Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2578 2585 19965662 10.1182/blood-2009-08-236471 1:CAS:528:DC%2BC3cXksFOhs70%3D
21. K Lin M Glenn R Harris A Duckworth S Dennett J Cawley, et al. 2006 c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications Cancer Res 66 7801 7809 16885384 10.1158/0008-5472.CAN-05-3901 1:CAS:528:DC%2BD28XnsFyqs7w%3D
22. A Sawitsky K Rai O Glidewell R Silver 1977 Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia Blood 50 1049 1059 336116 1:STN:280: DyaE1c%2FktVOrtg%3D%3D
23. R Bassan G Rossi E Pogliani E Di Bona E Angelucci I Cavattoni, et al. 2010 Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: northern Italy leukemia group protocol 09/00 J Clin Oncol 28 3644 3652 20606084 10.1200/JCO.2010.28.1287 1:CAS:528:DC%2BC3cXhtFSksb3L